¼¼°èÀÇ ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀå
Controlled Release Drug Delivery
»óǰÄÚµå : 1766948
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 294 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 911¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 610¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 6.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 911¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Çǵå¹é Á¦¾îÇüÀº CAGR 7.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 263¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ȱ¼ºÈ­ Á¶ÀýÇü ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 158¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 10.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀåÀº 2024³â¿¡ 158¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 218¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 10.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.5%¿Í 6.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹æÃâ Á¦¾îÇü ¾à¹°Àü´ÞÀÌ Ä¡·á Á¢±Ù¹ýÀ» ¾î¶»°Ô º¯È­½Ãų °ÍÀΰ¡?

¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á È¿°ú¸¦ ÃÖÀûÈ­Çϰí, ÀϰüµÇ°í Àå½Ã°£ÀÇ ¾à¹° ¹æÃâÀ» Á¦°øÇÏ¿© Á¦¾à »ê¾÷À» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ÇÏ·ç¿¡ ¿©·¯ ¹ø º¹¿ëÇØ¾ß ÇÏ´Â ±âÁ¸ÀÇ ¾à¹°Àü´Þ ¹æ½Ä°ú ´Þ¸®, ¹æÃâ Á¦¾î ½Ã½ºÅÛÀº Àå±â°£¿¡ °ÉÃÄ Á¡ÁøÀûÀ¸·Î ¾à¹°À» ¹æÃâÇÏ¿© Ç÷·ù ³» ¾à¹° ³óµµ¸¦ ¾ÈÁ¤È­½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ½ÉÇ÷°üÁúȯ, ´ç´¢º´, ¾Ï µî ¾à¹° ³óµµ¸¦ ¾ÈÁ¤È­½ÃŰ´Â °ÍÀÌ È¿°úÀûÀÎ Ä¡·á¿¡ ÇʼöÀûÀÎ ¸¸¼ºÁúȯ °ü¸®¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¹æÃâ Á¦¾î ½Ã½ºÅÛÀº Á¤Á¦, ĸ½¶, ÀÓÇöõÆ®, ÁÖ»çÁ¦, ¸¶ÀÌÅ©·Î½ºÇÇ¾î µî ´Ù¾çÇÑ ÇüÅ·ΠÁ¦°øµÇ¸ç, °¢°¢Àº ƯÁ¤ Ä¡·á ¿ä±¸¿¡ ¸Â°Ô Á¶Á¤µË´Ï´Ù. ¹æÃâ Á¦¾î ½Ã½ºÅÛÀº Åõ¿© Ƚ¼ö¸¦ ÁÙÀÓÀ¸·Î½á ȯÀÚÀÇ º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½ÃÄÑ Àå±â Ä¡·áÀÇ ¼º°ø¿¡ Áß¿äÇÑ ¿ä¼Ò·Î ÀÛ¿ëÇÕ´Ï´Ù.

¹æÃâ Á¦¾î Á¦Á¦ÀÇ °³¹ß·Î ƯÁ¤ Á¶Á÷À̳ª Àå±â¸¦ Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖ°Ô µÇ¾î ¾àÈ¿°¡ Çâ»óµÇ°í Ç¥Àû ¿Ü ÀÛ¿ëÀÌ °¨¼ÒÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, ¾Ï Ä¡·á¿¡ »ç¿ëµÇ´Â À̽ÄÇü ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ±¹¼Ò Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí, °Ç°­ÇÑ Á¶Á÷¿¡ ´ëÇÑ ³ëÃâÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¾¾ç¿¡ ´õ ³ôÀº ³óµµÀÇ ¾à¹°À» Á÷Á¢ Àü´ÞÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç¥ÀûÈ­µÈ Á¢±Ù ¹æ½ÄÀº °¢ ȯÀÚÀÇ °íÀ¯ÇÑ Çʿ信 µû¶ó Ä¡·áÇÏ´Â ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½Ã½ºÅÛÀº º¸´Ù Á¤È®Çϰí È¿°úÀûÀ̸ç ȯÀÚ Ä£È­ÀûÀÎ Ä¡·á¹ýÀ» °¡´ÉÄÉ ÇÏ¿© Çö´ë ÀÇÇÐÀÇ ±ÍÁßÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

¹æÃâ Á¦¾îÇü ¾à¹°Àü´ÞÀ» Áö¿øÇÏ´Â ±â¼úÀº ¹«¾ùÀΰ¡?

¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀåÀº ¾à¹° ¹æÃâ ¼Óµµ¿Í Ç¥Àû ƯÀ̼ºÀ» Á¤È®ÇÏ°Ô Á¦¾îÇÒ ¼ö ÀÖ´Â ¸î °¡Áö ÷´Ü ±â¼ú¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå ³Î¸® »ç¿ëµÇ´Â ±â¼ú Áß ÇϳªÀÎ Æú¸®¸Ó ±â¹Ý ½Ã½ºÅÛÀº »ýºÐÇØ¼º ¶Ç´Â ºñ»ýºÐÇØ¼º Æú¸®¸Ó¸¦ Æ÷ÇÔÇÏ°í ¾à¹°À» ĸ½¶È­ÇÏ¿© Æú¸®¸Ó°¡ ºÐÇØµÊ¿¡ µû¶ó Á¡ÁøÀûÀ¸·Î ¹æÃâÇÏ´Â ±â¼úÀÔ´Ï´Ù. Æú¸®¶ôÆ®»ê-ÄÚ-±Û¸®ÄÝ»ê(PLGA)°ú °°Àº Æú¸®¸Ó´Â »ýüÀûÇÕ¼º°ú ºÐÇØ ¼Óµµ Á¶ÀýÀÌ °¡´ÉÇÏ¿© ƯÁ¤ Ä¡·á ¿ä±¸¿¡ ¸ÂÃâ ¼ö Àֱ⠶§¹®¿¡ ¹æÃâ Á¦¾î Á¦Á¦·Î¼­ ÀαⰡ ÀÖ½À´Ï´Ù. ¸®Æ÷¼Ø, ³ª³ë ĸ½¶È­, ÇÏÀ̵å·Î°Ö ±â¹Ý ½Ã½ºÅÛÀº ¾à¹° ¼­¹æÈ­¸¦ ´Þ¼ºÇÏ´Â µ¥ »ç¿ëµÇ´Â ´Ù¸¥ ÷´Ü ±â¼úÀ̸ç, Ä£¼ö¼º ¹× ¼Ò¼ö¼º ¾à¹°À» ¸ðµÎ ĸ½¶È­ÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» Á¦°øÇÕ´Ï´Ù.

³ª³ë±â¼úÀº ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ¿¡µµ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ƯÈ÷ ¾à¹°À» Ç¥Àû ¼¼Æ÷ ¹× Á¶Á÷¿¡ Á÷Á¢ Àü´ÞÇÒ ¼ö ÀÖ´Â ³ª³ë½ºÄÉÀÏ Ä³¸®¾îÀÇ °³¹ßÀÌ Áß¿äÇÕ´Ï´Ù. ³ª³ëÀÔÀÚ, ¸®Æ÷¼Ø, ¹Ì¼¿Àº »ýü ÀÌ¿ë·üÀ» ³ôÀ̰í, ¾à¹°ÀÇ ¾ÈÁ¤¼ºÀ» Çâ»ó½Ã۸ç, Ä¡·á ¿µ¿ªÀ» ³ÐÇôÁÖ¸ç, pH³ª ¿Âµµ¿Í °°Àº ƯÁ¤ »ý¸®Àû Æ®¸®°Å¿¡ ¹ÝÀÀÇÏ´Â ½º¸¶Æ® Àü´Þ ½Ã½ºÅÛÀº ü³»ÀÇ Æ¯Á¤ »óÅ¿¡ ¹ÝÀÀÇÏ¿© ¾à¹°À» Á¤È®ÇÏ°Ô ¹æÃâÇÒ ¼ö Àֱ⠶§¹®¿¡ »õ·Î¿î °ü½É ºÐ¾ß·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, 3D ÇÁ¸°ÆÃÀº ¾à¹° ¹æÃâ ÇÁ·ÎÆÄÀÏÀ» ¸ÂÃã Á¦ÀÛÇϱâ À§ÇØ ¿¬±¸µÇ°í ÀÖÀ¸¸ç, º¹ÀâÇÑ ¾à¹° ¹æÃâ ÆÐÅÏÀÇ Á¦Á¶¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¹æÃâ Á¦¾îÇü ¾à¹°Àü´ÞÀÇ ÇѰ踦 ¶Ù¾î³Ñ¾î ´Ù¾çÇÑ Áúº´¿¡ ´ëÇØ ¸ÂÃãÇüÀ¸·Î ¸Å¿ì È¿°úÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

¹æÃâ Á¦¾îÇü ¾à¹°Àü´ÞÀÇ ÁÖ¿ä ¿ëµµ´Â?

¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ¿©·¯ Ä¡·á ºÐ¾ß¿¡ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÇ¾î ¸¸¼º ¹× ±Þ¼º ÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀÇ ¿ä±¸¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù. Á¾¾çÇп¡¼­ ¼­¹æÇü ½Ã½ºÅÛÀº È­Çпä¹ý ¾à¹°À» Àå±â°£¿¡ °ÉÃÄ Àü´ÞÇÏ¿© Àü½Å µ¶¼ºÀ» ÁÙÀ̸鼭 Á¾¾ç ³» È¿°úÀûÀÎ ¾à¹° ³óµµ¸¦ À¯ÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¾à¹° ¿ëÃâ ½ºÅÙÆ®¿Í °°Àº À̽ÄÇü ¾à¹°Àü´Þ ±â±â´Â Ç÷°ü¼ºÇü¼ú ÈÄ Ç÷°üÀÇ ÀçÇùÂøÀ» ¹æÁöÇϱâ À§ÇØ ±¹¼ÒÀûÀ¸·Î ¾à¹°À» ¹æÃâÇÏ´Â ½ÉÇ÷°ü Ä¡·á¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, ´ç´¢º´ °ü¸®¿¡¼­µµ ¹æÃâ Á¦¾îÇü Àν¶¸° Á¦Á¦´Â º¸´Ù ¾ÈÁ¤ÀûÀÎ Ç÷´ç Á¶ÀýÀ» °¡´ÉÇÏ°Ô Çϰí, Àν¶¸° Åõ¿© ºóµµ¸¦ ÁÙ¿© ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãŵ´Ï´Ù.

½Å°æÇÐ ¶ÇÇÑ ¹æÃâ Á¦¾îÇü ¾à¹°Àü´ÞÀÌ Å« ÁøÀüÀ» ÀÌ·ç°í ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¼­¹æÇü Á¦Á¦´Â ÆÄŲ½¼º´, °£Áú, ¸¸¼º ÅëÁõ Ä¡·á¿¡ »ç¿ëµÇ¸ç, Áö¼ÓÀûÀÎ ¾à¹°Àü´ÞÀ» ÅëÇØ Áõ»óÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº È£¸£¸ó º¸Ãæ ¿ä¹ý¿¡µµ Ȱ¿ëµÇ¾î È£¸£¸ó ³óµµ¸¦ ÀÏÁ¤ÇÏ°Ô À¯ÁöÇÏ¿© È£¸£¸ó ³óµµ º¯µ¿¿¡ µû¸¥ ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½Ã½ºÅÛÀº º¹ÀâÇÑ Åõ¾à ½ºÄÉÁÙÀ» ÁؼöÇϱ⠾î·Á¿î ¼Ò¾Æ°ú ¹× ³ë³âÃþ ȯÀڵ鿡°Ôµµ À¯¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚÀÇ Æ¯Á¤ ¿ä±¸¿¡ ¸Â°Ô ¹æÃâ ÇÁ·ÎÆÄÀÏÀ» Á¶Á¤ÇÒ ¼ö Àֱ⠶§¹®¿¡ ¼­¹æÇü Á¦Á¦´Â ȯÀÚ Áß½ÉÀÇ È¿°úÀûÀÎ Ä¡·á¸¦ À§ÇÑ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼ºÁúȯÀÇ Áõ°¡, ¾à¹°Àü´Þ ±â¼úÀÇ ¹ßÀü, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´, ¾Ï, ½ÉÇ÷°üÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó Áö¼ÓÀûÀ̰í Ç¥ÀûÈ­µÈ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹æÃâ Á¦¾î Á¦Á¦´Â ¾ÈÁ¤ÀûÀÎ Ä¡·á ¼öÁØÀ» °¡´ÉÇÏ°Ô Çϸç, ÀÌ´Â Àå±âÀûÀÎ ÁúȯÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ³ª³ë±â¼ú, °íºÐÀÚ °úÇÐ, »ý¸í°øÇÐÀ» Áß½ÉÀ¸·Î ÇÑ ±â¼ú ¹ßÀüÀº Á¤È®¼º°ú ȯÀÚ ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â Çõ½ÅÀûÀÎ ¹æÃâ Á¦¾î ½Ã½ºÅÛ °³¹ßÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

ȯÀÚ Áß½ÉÀÇ ÀÇ·á ¼­ºñ½º·ÎÀÇ ÀüȯÀº ¶Ç ´Ù¸¥ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ̸ç, ¹æÃâ Á¦¾î ½Ã½ºÅÛÀº Åõ¿© Ƚ¼ö¸¦ ÁÙÀ̰í, ƯÈ÷ °í·ÉÀÚ ¹× º¹ÀâÇÑ ¾à¹° ¿ä¹ýÀ» °¡Áø »ç¶÷µéÀÇ º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½Ãŵ´Ï´Ù. ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀº Á¦¾à»çÀÇ R&D ÅõÀÚ Áõ°¡¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ °³°³Àο¡ ¸Â´Â Ä¡·á¸¦ °­Á¶ÇÏ´Â ¸ÂÃã ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¸ÂÃãÇü ¾à¹°Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí Çö´ë ÀÇ·á ¹× Ä¡·á °³¹ßÀÇ ÇÙ½É ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

¹æÃâ ¸ÞÄ¿´ÏÁò(Çǵå¹é Á¦¾î, Ȱ¼ºÈ­ Á¶Àý, È­ÇРȰ¼ºÈ­, Æú¸®¸Ó ±â¹Ý ½Ã½ºÅÛ, ¸¶ÀÌÅ©·Î ·¹Àú¹ö ÆÄƼ¼Ç), ¿ëµµ(°æ±¸ Á¦¾î, Á¤·® ÈíÀÔ, ÁÖ»çÁ¦, °æÇÇ¡¤¾È±¸¿ë ÆÐÄ¡, ÁÖÀÔ ÆßÇÁ, ¾à¹° ¿ëÃâ ½ºÅÙÆ®)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Controlled Release Drug Delivery Market to Reach US$91.1 Billion by 2030

The global market for Controlled Release Drug Delivery estimated at US$61.0 Billion in the year 2024, is expected to reach US$91.1 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Feedback Regulated, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$26.3 Billion by the end of the analysis period. Growth in the Activation-Modulated segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$15.8 Billion While China is Forecast to Grow at 10.3% CAGR

The Controlled Release Drug Delivery market in the U.S. is estimated at US$15.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.8 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Controlled Release Drug Delivery Market - Key Trends & Drivers Summarized

How Is Controlled Release Drug Delivery Transforming Therapeutic Approaches?

Controlled release drug delivery systems are reshaping the pharmaceutical landscape by providing a consistent and prolonged release of medication, which optimizes therapeutic effects while minimizing side effects. Unlike conventional drug delivery methods that often require multiple doses throughout the day, controlled release systems enable medications to be released gradually over an extended period, ensuring steady drug levels in the bloodstream. This technology is especially beneficial for managing chronic conditions, such as cardiovascular diseases, diabetes, and cancer, where maintaining stable drug concentrations is crucial for effective treatment. Controlled release systems can take various forms, including tablets, capsules, implants, and injectable microspheres, each tailored to specific therapeutic needs. By reducing the frequency of dosing, controlled release systems also improve patient adherence, a key factor in the success of long-term treatments.

The development of controlled release formulations has made it possible to target specific tissues or organs, enhancing drug efficacy and reducing off-target effects. For example, implantable drug delivery systems used in cancer therapy can provide localized treatment, delivering higher drug concentrations directly to tumors while minimizing exposure to healthy tissues. This targeted approach is helping to advance personalized medicine, where treatments are tailored to the unique needs of each patient. As a result, controlled release drug delivery systems are becoming a valuable tool in modern medicine, enabling more precise, effective, and patient-friendly therapeutic options.

What Technologies Are Powering Controlled Release Drug Delivery?

The controlled release drug delivery market is driven by several advanced technologies that enable precise control over drug release rates and target specificity. Polymer-based systems are one of the most widely used technologies, involving biodegradable or non-biodegradable polymers that encapsulate the drug and release it gradually as the polymer breaks down. Polymers like poly(lactic-co-glycolic acid) (PLGA) are popular in controlled release formulations due to their biocompatibility and adjustable degradation rates, which can be tailored for specific therapeutic needs. Liposomes, nanoencapsulation, and hydrogel-based systems are other advanced technologies used to achieve sustained drug release, offering the ability to encapsulate both hydrophilic and hydrophobic drugs.

Nanotechnology has also had a significant impact on controlled release drug delivery, particularly in the development of nanoscale carriers that can deliver drugs directly to target cells or tissues. Nanoparticles, liposomes, and micelles enhance bioavailability and improve drug stability, extending the therapeutic window. Smart delivery systems, which respond to specific physiological triggers like pH or temperature, are an emerging area of interest, as they allow drugs to be released precisely in response to certain conditions in the body. Additionally, 3D printing is being explored for custom-tailoring drug release profiles, enabling the production of complex drug release patterns. These technologies are pushing the boundaries of controlled release drug delivery, making it possible to create customized and highly effective treatments for a range of diseases.

What Are the Key Applications of Controlled Release Drug Delivery?

Controlled release drug delivery systems have broad applications across multiple therapeutic areas, addressing the needs of patients with chronic and acute conditions. In oncology, controlled release systems are used to deliver chemotherapy drugs over a prolonged period, helping to maintain effective drug concentrations in tumors while reducing systemic toxicity. Implantable drug delivery devices, such as drug-eluting stents, are widely used in cardiovascular treatments, where they release medication locally to prevent blood vessel re-narrowing following angioplasty. Similarly, in diabetes management, controlled release insulin formulations allow for more stable glucose control, reducing the frequency of insulin administration and improving patients' quality of life.

Neurology is another area where controlled release drug delivery is making significant advancements. For instance, controlled release formulations are used to treat Parkinson’s disease, epilepsy, and chronic pain, providing continuous drug delivery to manage symptoms effectively. These systems are also utilized in hormone replacement therapy, where they offer consistent hormone levels and reduce the side effects associated with fluctuating hormone concentrations. Furthermore, controlled release drug delivery systems are beneficial in pediatrics and geriatrics, where adherence to complex dosing schedules can be challenging. The ability to tailor release profiles to meet the specific needs of these patients makes controlled release an essential tool for effective, patient-centered care.

What Is Driving Growth in the Controlled Release Drug Delivery Market?

The growth in the controlled release drug delivery market is driven by several factors, including the increasing prevalence of chronic diseases, advancements in drug delivery technology, and the growing demand for personalized medicine. As the incidence of chronic diseases such as diabetes, cancer, and cardiovascular conditions rises globally, the need for sustained and targeted drug delivery systems is increasing. Controlled release formulations allow for steady therapeutic levels, which are essential in managing long-term conditions effectively. Technological advancements, particularly in nanotechnology, polymer science, and biotechnology, are also accelerating the development of innovative controlled release systems that offer enhanced precision and patient compliance.

The shift toward patient-centered healthcare is another major growth driver, as controlled release systems reduce dosing frequency and improve adherence, especially for populations like the elderly and those with complex medication regimens. Regulatory support for advanced drug delivery systems, along with increased investment in R&D from pharmaceutical companies, is further boosting market growth. Additionally, the rising focus on personalized medicine, which emphasizes treatments tailored to individual patients, is creating demand for customizable drug delivery solutions. Together, these factors are propelling the expansion of the controlled release drug delivery market, making it a critical component of modern healthcare and therapeutic development.

SCOPE OF STUDY:

The report analyzes the Controlled Release Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Release Mechanism (Feedback Regulated, Activation-Modulated, Chemically Activated, Polymer-based Systems, Micro Reservoir Partition); Application (Oral Controlled, Metered Dose Inhalers, Injectables, Transdermal & Ocular Patches, Infusion Pumps, Drug Eluting Stents)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â